Abstract:Background: Doxorubicin, a first-line chemotherapeutic drug for breast cancer, kills cancer cells by inducing DNA-crosslinking damage. Dysregulated micro-RNA (miRNA) is associated with the drug resistance of tumors. However, little is known about the effect of miRNA-140-3p on DOX resistance of breast cancer. Methods: The miRNA microarray was used to sequence the transcripts of DOX-chemoresistant breast cancer tissues and DOX-chemosensitive tissues. Then, the breast cancer tissue chip in the GEO database was also analyzed to screen the target gene. Flow cytometry, in situ hybridisation (ISH), immunohistochemistry (IHC), Western blot, cell proliferation assay, real-time PCR analyses (qRT-PCR), and pull-down assay were used to explore the effects of miRNA-140-3p and programmed death ligand-1 (PD-L1) on the chemoresistance of DOX-resistant breast cancer cells treated with DOX. In vivo, the DOX-resistant breast cancer cell lines treated with miRNA-140-3p overexpression were injected subcutaneously into mice to construct breast cancer subcutaneous xenograft tumor models. Results: Based on miRNA microarray, GEO database, and bioinformatics analysis, it was found that miRNA-140-3p and PD-L1 are the core molecules in the DOX resistance regulatory network in breast cancer, and lower miRNA-140-3p and higher PD-L1 expression levels were observed in DOX-resistant breast cancer tissues and cells. IHC results showed that compared with breast cancer tissues with high miRNA-140-3p expression, PD-L1 protein expression levels in breast cancer tissues with low miRNA-140-3p were significantly higher (P<0.01). Moreover, compared with DOX-sensitive tissues, the levels of PD-L1 protein expression in DOX-resistant tissues were significantly higher (P<0.01). In in vitro and in vivo experiments, the introduction of miRNA-140-3p decreased PD-L1 expression. Mechanically, we found that the MCF-7/DOX and HS598T/DOX cells pretreated with miRNA-140-3p inhibitor or exosomes containing PD-L1 have higher stemness and lower apoptosis rate, which can be abrogated by co-treating cells with anti-PD-L1 antibody or miRNA-140-3p mimic. Conclusions: MiRNA-140-3p can suppress PD-L1 expression in breast cancer cell-derived exosomes, thereby attenuating the chemoresistance induced by DOX in breast cancer.

miR-193b Modulates Resistance to Doxorubicin in Human Breast Cancer Cells by Downregulating MCL-1.

MiR-205 suppressed the malignant behaviors of breast cancer cells by targeting CLDN11 via modulation of the epithelial-to-mesenchymal transition

MiR-181b Promotes Chemoresistance in Breast Cancer by Regulating Bim Expression.

Mir-181b Modulates Multidrug Resistance By Targeting Bcl2 In Human Cancer Cell Lines

Mir-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells.

miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.

Mir-200Bc/429 Cluster Modulates Multidrug Resistance of Human Cancer Cell Lines by Targeting BCL2 and XIAP.

MiR-181 a Enhances Drug Sensitivity in Mitoxantone-Resistant Breast Cancer Cells by Targeting Breast Cancer Resistance Protein ( BCRP / ABCG 2 )

Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression

Mir-135A/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1

miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.

Exosomes regulate doxorubicin resistance in breast cancer via miR-34a-5p/NOTCH1

Tumor Suppressive Microrna-193B Promotes Breast Cancer Progression Via Targeting DNAJC13 and RAB22A.

Mir-140-5p Inhibits the Proliferation and Enhances the Efficacy of Doxorubicin to Breast Cancer Stem Cells by Targeting Wnt1

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin

Mir-181B Increases Drug Sensitivity in Acute Myeloid Leukemia Via Targeting HMGB1 and Mcl-1.

MiR-487a Resensitizes Mitoxantrone (Mx)-Resistant Breast Cancer Cells (MCF-7/MX) to MX by Targeting Breast Cancer Resistance Protein (BCRP/ABCG2)

Mir-520B Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.

miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2

Mir-137 Alleviates Doxorubicin Resistance in Breast Cancer Through Inhibition of Epithelial-Mesenchymal Transition by Targeting DUSP4